Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02831751
Recruitment Status : Unknown
Verified August 2016 by Medicago.
Recruitment status was:  Active, not recruiting
First Posted : July 13, 2016
Last Update Posted : September 1, 2016
Sponsor:
Information provided by (Responsible Party):
Medicago

Brief Summary:
This Phase 2 Quadrivalent VLP Vaccine study is intended to replicate and extend the immunogenicity and safety results obtained in earlier Phase 1-2 and Phase 2 studies. The study is being conducted to evaluate that the immunogenicity profile of the Quadrivalent VLP Vaccine meets the US Center for Biologics Evaluation and Research (CBER) licensure criteria and to evaluate if the immunogenicity and the safety profile of the Quadrivalent VLP Vaccine is acceptable and comparable to that of the FluLaval® Tetra and Fluzone® High-Dose (HD). The study will also help to define the optimal dose in this population, establish potential competitive advantages, and support the design of future studies.

Condition or disease Intervention/treatment Phase
Virus Diseases RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Biological: 30 µg/strain of Quadrivalent VLP Vaccine Biological: 60 µg/strain of Quadrivalent VLP Vaccine Biological: FluLaval® Tetra (15 µg/strain) Biological: Fluzone® High-Dose (60 µg/strain) Phase 2

Detailed Description:

This randomized, observer-blind, multicenter, Phase 2 study will be conducted at multiple sites across the United States and Canada.

The influenza strain composition of the Quadrivalent VLP Vaccine used in this study includes 2 influenza A virus strains (A/California/7/2009 [H1N1] and A/Switzerland/9715293/2013 [H3N2]) and 2 influenza B virus strains (B/Phuket/3073/2013 [Yamagata lineage] and B/Brisbane/60/2008 [Victoria lineage]), based on the 2015-2016 recommended World Health Organization (WHO) strains for vaccination in the Northern hemisphere.

Approximately 1000 elderly male and female subjects, aged 65 years or older, will be randomized in a 1:1:1:1 ratio to 1of 4 parallel treatment groups such that 500 subjects receive Quadrivalent VLP Vaccine (250 each for the 30 µg/strain and 60 µg/strain groups), 250 subjects receive FluLaval® Tetra (15 µg/strain) and 250 subjects receive Fluzone® HD (60 µg/strain). Subjects in each group will be stratified into 2 age strata: 65 to 74 years and 75 years old and older, where 70 % of subjects will be enrolled into the 65 to 74 years old age group and 30 % into the 75 years old or older group.

Subjects will participate in this study for approximately 8 months, during which 5 visits will be scheduled, and phone contact will be made on Day 1, Day 8, and every 2 months thereafter for up to 6 months post-Day 21 visit (Day 201). Blood samples will be collected for immunogenicity analyses at Days 0 and 21 for all subjects. Safety laboratory assessments will be performed at Screening, on Day 3 and within 48 hours of Day 3 results availability, for grade 3 or grade 4 abnormalities or if deemed necessary by the investigator or early termination. Subsequent follow-up of clinically significant laboratory abnormalities will be done according to the investigator's discretion.. Subjects will be monitored throughout the study for safety, including the reporting of solicited local and systemic reactions.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Randomized, Observer-Blind, Multicenter, Phase 2 Study to Assess the Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults of 65 Years of Age or Older
Study Start Date : April 2016
Actual Primary Completion Date : July 2016
Estimated Study Completion Date : January 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot

Arm Intervention/treatment
Experimental: 30 µg/strain of Quadrivalent VLP Vaccine Biological: 30 µg/strain of Quadrivalent VLP Vaccine
Single dose of non-adjuvanted Quadrivalent VLP Vaccine

Experimental: 60 µg/strain of Quadrivalent VLP Vaccine Biological: 60 µg/strain of Quadrivalent VLP Vaccine
Single dose of non-adjuvanted Quadrivalent VLP Vaccine

Active Comparator: FluLaval® Tetra (15 µg/strain) Biological: FluLaval® Tetra (15 µg/strain)
Single dose of a licensed quadrivalent vaccine
Other Name: FluLaval® Quadrivalent

Active Comparator: Fluzone® High-Dose (60 µg/strain) Biological: Fluzone® High-Dose (60 µg/strain)
Single dose of a licensed trivalent vaccine




Primary Outcome Measures :
  1. Immunogenicity assessed by the geometric mean titers (GMT) of hemagglutination inhibition (HI) antibody against the homologous influenza strains [ Time Frame: 21 days after injection ]
    Immunogenicity will be assessed by the geometric mean titers (GMT)


Secondary Outcome Measures :
  1. Immunogenicity assessed by GMT of HI antibody against heterologous strains [ Time Frame: 21 days after injection ]
  2. Immunogenicity assessed by GMT of microneutralization (MN) antibody against homologous and heterologous strains [ Time Frame: 21 days after injection ]
  3. Immunogenicity assessed by GMT of single radial hemolysis (SRH) antibody against homologous and heterologous strains [ Time Frame: 21 days after injection ]
  4. Immunogenicity assessed by cell-mediated immune (CMI) response against homologous and heterologous strains [ Time Frame: 21 days after injection ]
  5. Incidence of Solicited Local and Systemic Reactions [ Time Frame: 21 days after injection ]
  6. Incidence of Treatment-Emergent Adverse Events [ Time Frame: 21 days after injection ]
  7. Incidence of Abnormal Clinical Laboratory Tests [ Time Frame: 3 days after injection ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Subjects must meet all of the following inclusion criteria to be eligible for participation in this study:

  1. Subjects must be able to read, understand, and sign the informed consent form (ICF); complete study-related procedures; and communicate with the study staff at visits and by phone.
  2. Subjects are considered by the Investigator to be reliable and likely to cooperate with the assessment procedures and be available for the duration of the study.
  3. Male and female subjects must be 65 years of age or older at Screening (Visit 1).
  4. Subjects have a body mass index (BMI) of ≥ 18.0 and ≤ 32.4 kg/m2 at Day 0.
  5. Subjects must be in good general health prior to study participation (no more than 30 days prior to study vaccine administration) with no clinically relevant abnormalities that could jeopardize subject safety or interfere with study assessments as assessed by the Principal Investigator or Sub-Investigator (thereafter referred as Investigator) and determined by medical history, physical examination, biochemistry, hematology, and urinalysis.

Note: Subjects with a pre-existing chronic disease will be allowed to participate if the disease is stable and, according to the Investigator's judgment, the condition is unlikely to confound the results of the study or pose additional risk to the subject by participating in the study. Stable disease is generally defined as no new onset or exacerbation of pre-existing chronic disease 6 months prior to immunization. Based on the Investigator's judgment, a subject with more recent stabilization of a disease could also be eligible.

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded from participating in this study:

  1. According to the Investigator's opinion, history of significant acute or chronic, uncontrolled medical or neuropsychiatric illness. "Uncontrolled" is defined as:

    • Requiring a new medical or surgical treatment within one month prior to study vaccine administration;
    • Requiring a change in medication dosage during one month prior to study vaccine administration due to uncontrolled symptoms or drug toxicity, or for chronic diseases, significant change in medication dosage within 6 months prior to study vaccine administration based upon the investigator's judgment (elective dosage adjustments in stable subjects are acceptable).
  2. Any medical or neuropsychiatric condition or any history of excessive alcohol use or drug abuse which, in the Investigator's opinion, would render the subject unable to provide informed consent or unable to provide valid safety observations and reporting.
  3. Any autoimmune disease other than hypothyroidism on stable replacement therapy or any confirmed or suspected immunosuppressive condition or immunodeficiency including known or suspected human immunodeficiency virus (HIV), Hepatitis B or C infection, or the presence of lymphoproliferative disease.
  4. Administration or planned administration of any non-influenza vaccine within 30 days prior to randomization up to blood sampling at Day 21. Immunization on an emergency basis will be evaluated case-by-case by the Investigator.
  5. Administration of any adjuvanted or investigational influenza vaccine within 1 year prior to randomization or planned administration prior to the completion of Day 201.
  6. Administration of any 'standard', non-adjuvanted influenza vaccine (e.g., live attenuated trivalent/quadrivalent inactivated influenza vaccine intranasal or split trivalent/quadrivalent inactivated influenza vaccine by either intradermal or intramuscular [IM] route) within 6 months prior to randomization and up to completion of Day 21 visit.
  7. Use of any investigational or non-registered product within 30 days or 5 half-lives, whichever is longer, prior to randomization or planned use during the study period. Subjects may not participate in any other investigational or marketed drug study while participating in this study until Day 201 visit.
  8. Treatment with systemic glucocorticoids at a dose exceeding 10 mg of prednisone per day, or equivalent for more than 7 consecutive days or for 10 or more days in total, within one month of study vaccine administration, any other cytotoxic or immunosuppressant drug, or any immunoglobulin preparation within 3 months of vaccination and until the completion of Day 21 visit. Low doses of nasal or inhaled glucocorticoids are allowed. Topical steroids are permitted.
  9. Any significant disorder of coagulation including treatment with warfarin derivatives or heparin. Persons receiving prophylactic anti-platelet medications (e.g., low-dose aspirin [no more than 325 mg/day]), and without a clinically apparent bleeding tendency are eligible. Subjects treated with new generation drugs that do not increase the risk of intramuscular bleeding (e.g. clopidogrel) are also eligible.
  10. History of allergy to any of the constituents of the Quadrivalent VLP vaccine (including H1N1, H3N2, B/Bris, and B/Phuket), to any components of the licensed quadrivalent/trivalent vaccine, or tobacco allergy.
  11. History of anaphylactic allergic reactions to any food, medication, or bee sting.
  12. Any history of serious asthma (e.g., status asthmaticus, hospitalization for asthma control) or recurrent asthma episodes requiring medical attention in the last 3 years (≥ 1 episode/year)
  13. Continuous use of antihistamines in the last 4 weeks prior to immunization or use of antihistamines 48 hours prior to study immunization.
  14. Use of prophylactic medications (e.g. acetaminophen/paracetamol, aspirin, naproxen, or ibuprofen) within 24 hours of randomization to prevent or pre-empt symptoms due to vaccination. Subject discovered to have taken a prophylactic medication within the 24 hours prior to planned randomization must be delayed until the 24 hours period is met.
  15. Have a rash, dermatological condition, tattoos, muscle mass, or any other abnormalities at injection site that may interfere with injection site reaction rating.
  16. Have received a blood transfusion within 90 days prior to study vaccination.
  17. Have abnormal Vital Signs defined as: systolic Blood Pressure (BP) > 140 mmHg and/or diastolic BP ≥ 90mmHg, heart rate ≤ 45 beats/min and ≥ 100 beats/min. Even if one or more vital signs are out of the acceptable ranges, a subject may still be included in the study based on Investigator's judgment (e.g. a resting heart rate ≤ 45 in highly-trained athletes). Presence of any febrile illness (including oral temperature (OT) ≥ 38.0 ˚C within 24 hours prior to immunization). Such subjects may be re-evaluated for enrolment after resolution of illness.
  18. Cancer or treatment for cancer within 3 years of study vaccine administration. Persons with a history of cancer who are disease-free without treatment for 3 years or more are eligible. Persons with treated and uncomplicated basal cell carcinoma of the skin are eligible. Person with non-treated, non-disseminated local prostate cancer are eligible.
  19. Identified as an Investigator or employee of the Investigator or clinical site with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study or any employees of Medicago.
  20. Subject with a history of Guillain-Barre Syndrome

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02831751


Locations
Layout table for location information
United States, California
Paradigm Research - Redding
Redding, California, United States, 96001
United States, Florida
Broward Research Group (BRG)
Hollywood, Florida, United States, 33024
Miami Research Associates (MRA)
South Miami, Florida, United States, 33143
United States, Georgia
Meridian Clinical Research - Savannah
Savannah, Georgia, United States, 31406
United States, Nebraska
Meridian Clinical Research - Omaha
Omaha, Nebraska, United States, 68134
United States, New York
Regional Clinical Research (RCR)
Endwell, New York, United States, 13760
Canada, Ontario
INC Research Toronto
Toronto, Ontario, Canada, M5V 2T3
Topstone Research
Toronto, Ontario, Canada, M9C 4Z5
Canada, Quebec
Manna Research
Lévis, Quebec, Canada, G6W OM5
Omnispec Clinical Research
Mirabel, Quebec, Canada, J7J 2K8
Diex Research Montreal
Montreal, Quebec, Canada, H2Y 1S1
McGill University Health Center - Vaccine Study Center (MUHC)
Pierrefonds, Quebec, Canada, H9H 4Y6
Diex Research Sherbroooke
Sherbroooke, Quebec, Canada, J1H 1Z1
Canada
Équipe de recherche en vaccination du CHU de Québec-Université Laval (CHU)
Quebec, Canada, G1E 7G9
Centre de Recherche St-Louis
Quebec, Canada, G1W 4R4
Sponsors and Collaborators
Medicago
Investigators
Layout table for investigator information
Principal Investigator: Pierre Lachance, MD Centre de Recherche St-Louis, Quebec, Canada
Principal Investigator: Marc Dionne, MD Équipe de recherche en vaccination du CHU de Québec-Université Laval (CHU), Quebec, Canada
Principal Investigator: Michael Libman, MD McGill University Health Center - Vaccine Study Center (MUHC), Montreal, Canada
Principal Investigator: Trevor Wesson, MD Diex Research Montreal, Montreal, Canada
Principal Investigator: Ginette Girard, MD Diex Research Sherbrooke, Sherbrooke, Canada
Principal Investigator: Deepen Patel, MD Topstone Research, Toronto, Canada
Principal Investigator: Gérald Vallières, MD Manna Research, Lévis, Canada
Principal Investigator: Luis Robles, MD INC Research Toronto, Inc., Toronto, Canada
Principal Investigator: Guy Tellier, MD Omnispec Clinical Research Inc, Mirabel, Canada
Principal Investigator: Diane R Krieger, MD Miami Research Associates (MRA), Miami (FL), USA
Principal Investigator: David J Seiden, MD Broward Research Group (BRG), Hollywood (FL), USA
Principal Investigator: Suchet R Patel, MD Regional Clinical Research (RCR), Endwell (NY), USA
Principal Investigator: Paul Bradley, MD Meridian Clinical Research, Savannah (GA), USA
Principal Investigator: Brandon J Essink, MD Meridian Clinical Research, Omaha (NE), USA
Principal Investigator: Jamshid Saleh, MD Paradigm Research, Redding (CA), USA

Layout table for additonal information
Responsible Party: Medicago
ClinicalTrials.gov Identifier: NCT02831751     History of Changes
Other Study ID Numbers: CP-Q14VLP-010
First Posted: July 13, 2016    Key Record Dates
Last Update Posted: September 1, 2016
Last Verified: August 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Medicago:
Influenza
Human
RNA Virus Infections
Immulogic
Immunogenic Factors
Physiological Effects of Drug
Virus Diseases
Orthomyxoviridae Infections
Infection

Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Influenza, Human
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
RNA Virus Infections
Orthomyxoviridae Infections
Vaccines
Immunologic Factors
Physiological Effects of Drugs